Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inotuzumab Ozogamicin vs Investigator's Choice in Relapsed/Refractory ALL
NCT01564784Phase 3Completed
- Sponsor
- Pfizer
- Start
- Aug 2012
- Primary completion
- Mar 2016
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 20
01
Overview
A Phase 3 trial of inotuzumab ozogamicin in acute lymphoblastic leukemia (ALL), sponsored by Pfizer. Started Aug 2012; status: completed.
02
Drugs
inotuzumab ozogamicin
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT01564784.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01564784.